# A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

> **NCT00528879** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 915 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00528879
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-11
- **Final completion:** 2010-05
- **Target enrollment:** 915 (ACTUAL)
- **Last updated:** 2015-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528879, "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00528879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*